Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
Amphotericin B (AmB) continues to be the mainstay of therapy for serious fungal infections, despite its relatively toxic side-effect profile. Lipid preparations of the medication have been marketed in the past few years in an attempt to reduce some of these side effects, especially nephrotoxicity. Although 6 cases of severe hypertension associated with the use of AmB deoxycholate have been reported in the literature, no cases of hypertension associated with a lipid-containing preparation of the medication have been reported. We report here the first case of severe hypertension associated with the infusion of AmB lipid complex (ABLC) in a patient with multiple intraperitoneal and urinary fungal pathogens. We also provide a brief review of the previously reported cases of hypertension associated with the deoxycholate formulation of AmB.
Rowles
D M
DM
Department of Infectious Diseases, Wilford Hall Medical Center, Lackland Air Force Base, OH 45433, USA. David.Rowles@wpafb.af.mil
Fraser
S L
SL
D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy; D002648:Child; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000009:adverse effects* / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B